Panel Discussion: How the Industry is Leveraging Spatial Omics for ALS Target Discovery & Biomarkers?
- How is spatial omics transforming our understanding of ALS pathology compared with traditional bulk tissue or single-cell approaches?
- Which emerging ALS targets or molecular pathways have been most compellingly revealed through spatial transcriptomics, proteomics, or multi-omic integration?
- How can spatial omics data be translated into actionable biomarkers for clinical trials, including patient stratification, early detection, or monitoring therapeutic response?
- What are the key technical, analytical, and interpretational challenges in applying spatial omics to human ALS tissue, and how are industry and academia addressing these?
- How do collaborative approaches between pharma, academic centers, and genome institutes accelerate the path from spatial omics discovery to drug development?
- Looking forward, what role will AI and machine learning play in extracting meaningful insights from complex spatial omics datasets in ALS?